Session

IBD (Posters)

VIRTUAL BIOLOGICS CLINIC: A STREAMLINED MULTI-DISCIPLINARY TEAM (MDT) APPROACH TO IMPROVE INFLAMMATORY BOWEL DISEASE (IBD) CARE
VIRTUAL BIOLOGICS CLINIC: A STREAMLINED MULTI-DISCIPLINARY TEAM (MDT) APPROACH TO IMPROVE INFLAMMATORY BOWEL DISEASE (IBD) CARE

IBD (Posters)  et al.

CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE
CYTOMEGALOVIRUS IN INFLAMMATORY BOWEL DISEASE: USEFULNESS OF A POSITIVE RESULT WITH DIFFERENT DIAGNOSTIC TECHNIQUES IN TREATMENT CHOICE

IBD (Posters)  et al.

EVALUATION OF STRESS, ANXIETY, DEPRESSION LEVELS AND INTESTINAL GENE EXPRESSION IN NEWLY DIAGNOSED IBD PATIENTS
EVALUATION OF STRESS, ANXIETY, DEPRESSION LEVELS AND INTESTINAL GENE EXPRESSION IN NEWLY DIAGNOSED IBD PATIENTS

IBD (Posters)  et al.

EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE
EFFECTS OF ANTI-TNF-ALPHA AND ANTI-ALPHA4BETA7 DRUGS ON CIRCULATING DENDRITIC CELLS MIGRATORY CAPACITY IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

NEUTROPHIL-LYMPHOCYTE RATIO ROLE TO PREDICT DISEASE ACTIVITY AND SEVERITY IN ULCERATIVE COLITIS
NEUTROPHIL-LYMPHOCYTE RATIO ROLE TO PREDICT DISEASE ACTIVITY AND SEVERITY IN ULCERATIVE COLITIS

IBD (Posters)  et al.

IMPACT OF BIOLOGIC THERAPIES AND SMALL MOLECULES ON THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
IMPACT OF BIOLOGIC THERAPIES AND SMALL MOLECULES ON THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

IBD (Posters)  et al.

EARLY INTERVENTION WITH BIOLOGICS IN CROHN'S DISEASE - HOW EARLY IS EARLY?
EARLY INTERVENTION WITH BIOLOGICS IN CROHN'S DISEASE - HOW EARLY IS EARLY?

IBD (Posters)  et al.

INCIDENCE, PREVALENCE, DISEASE PHENOTYPE AND MAXIMAL THERAPEUTIC STEP IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT
INCIDENCE, PREVALENCE, DISEASE PHENOTYPE AND MAXIMAL THERAPEUTIC STEP IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

IBD (Posters)  et al.

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN CROHN’S DISEASE PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN CROHN’S DISEASE PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

IBD (Posters)  et al.

RISK OF AND RISK FACTORS FOR COLORECTAL CANCER IN ULCERATIVE COLITIS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT
RISK OF AND RISK FACTORS FOR COLORECTAL CANCER IN ULCERATIVE COLITIS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

IBD (Posters)  et al.

LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT
LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT

IBD (Posters)  et al.

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

IBD (Posters)  et al.

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

IBD (Posters)  et al.

NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY
NON-MEDICAL, MANDATORY SWITCH AMONG ADALIMUMAB BIOSIMILARS AND FROM THE ORIGINATOR ADALIMUMAB TO BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTS – A PROSPECTIVE, MULTICENTRE STUDY ON EFFICACY, DRUG SUSTAINABILITY AND SAFETY

IBD (Posters)  et al.

HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY
HEALTH-RELATED QUALITY OF LIFE WITH GUSELKUMAB INDUCTION AND MAINTENANCE THERAPY AS MEASURED BY PROMIS-29: RESULTS THROUGH WEEK 48 OF PHASE 2 GALAXI 1 STUDY

IBD (Posters)  et al.

OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

IBD (Posters)  et al.

EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY
EVALUATION OF OZANIMOD EFFICACY AND SAFETY IN OLDER PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS FROM THE PHASE 3 TRUE NORTH STUDY

IBD (Posters)  et al.

EFFECT OF TRANSITION CARE ON CLINICAL OUTCOMES AND TREATMENT ADHERENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: AN OBSERVATIONAL PROSPECTIVE STUDY
EFFECT OF TRANSITION CARE ON CLINICAL OUTCOMES AND TREATMENT ADHERENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: AN OBSERVATIONAL PROSPECTIVE STUDY

IBD (Posters)  et al.

ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

IBD (Posters)  et al.

IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

IBD (Posters)  et al.

Item 341 - 360 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
18
19 20 21 22 23 24 25 26 27 28 29 30 31